Publication Type:

Journal Article

Source:

International Journal of Clinical Rheumatology, Volume 6, Number 2, p.115-117 (2011)

URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-79955074990&partnerID=40&md5=30de5f7207be65432c26c42be2101f7d

Keywords:

angiotensin 2 receptor antagonist, bleomycin, bosentan, calcium channel blocking agent, continuous infusion, digital ulcer, dipeptidyl carboxypeptidase inhibitor, drug dosage form comparison, drug efficacy, drug half life, drug mechanism, drug safety, drug tolerability, erectile dysfunction, human, iloprost, ischemia, outcome assessment, patient compliance, phosphodiesterase inhibitor, phosphodiesterase V, placebo, priority journal, prostacyclin, prostacyclin derivative, pulmonary hypertension, quality of life, Raynaud phenomenon, review, scleroderma, sildenafil, skin ulcer, systemic sclerosis, tadalafil, ulcer, vasoconstriction, vasodilator agent

Notes:

cited By (since 1996)0

Cite this Research Publication

P. Da Shenoy and Agarwal, Vb, “Tadalafil: A new role in Raynaud's phenomenon?”, International Journal of Clinical Rheumatology, vol. 6, pp. 115-117, 2011.